Moody Aldrich Partners LLC Sells 26,605 Shares of Oruka Therapeutics, Inc. $ORKA

Moody Aldrich Partners LLC lessened its holdings in Oruka Therapeutics, Inc. (NASDAQ:ORKA) by 26.2% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 74,806 shares of the company’s stock after selling 26,605 shares during the quarter. Oruka Therapeutics accounts for approximately 1.2% of Moody Aldrich Partners LLC’s holdings, making the stock its 16th largest holding. Moody Aldrich Partners LLC’s holdings in Oruka Therapeutics were worth $6,231,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in the business. Algert Global LLC lifted its holdings in shares of Oruka Therapeutics by 3.5% during the second quarter. Algert Global LLC now owns 5,380 shares of the company’s stock worth $512,000 after purchasing an additional 180 shares during the period. GAMMA Investing LLC boosted its position in Oruka Therapeutics by 201.6% in the third quarter. GAMMA Investing LLC now owns 374 shares of the company’s stock valued at $31,000 after buying an additional 250 shares during the last quarter. Nykredit A S acquired a new position in Oruka Therapeutics in the 2nd quarter worth approximately $29,000. AlphaCentric Advisors LLC increased its holdings in Oruka Therapeutics by 5.8% in the 1st quarter. AlphaCentric Advisors LLC now owns 11,506 shares of the company’s stock worth $564,000 after buying an additional 626 shares during the period. Finally, Orion Capital Management LLC acquired a new position in Oruka Therapeutics in the 2nd quarter worth approximately $91,000. Institutional investors and hedge funds own 56.44% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have recently commented on ORKA. UBS Group upped their price objective on shares of Oruka Therapeutics from $100.00 to $130.00 and gave the company a “buy” rating in a report on Wednesday, July 1st. BTIG Research reiterated a “buy” rating and issued a $151.00 price objective on shares of Oruka Therapeutics in a research note on Monday, October 19th. Mizuho set a $120.00 target price on shares of Oruka Therapeutics in a report on Thursday, September 3rd. HC Wainwright reissued a “buy” rating on shares of Oruka Therapeutics in a report on Tuesday. Finally, Piper Sandler restated an “overweight” rating on shares of Oruka Therapeutics in a research report on Wednesday, October 7th. Ten research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $133.00.

Insiders Place Their Bets

In other Oruka Therapeutics news, insider Joana Goncalves sold 7,000 shares of Oruka Therapeutics stock in a transaction on Thursday, October 15th. The shares were sold at an average price of $74.81, for a total transaction of $523,670.00. Following the sale, the insider owned 31,771 shares of the company’s stock, valued at $2,376,788.51. The trade was a 18.05% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Arjun Agarwal sold 9,999 shares of the company’s stock in a transaction on Monday, October 12th. The stock was sold at an average price of $80.60, for a total transaction of $805,919.40. Following the sale, the senior vice president directly owned 14,219 shares of the company’s stock, valued at $1,146,051.40. The trade was a 41.29% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 154,950 shares of company stock valued at $14,102,680 in the last 90 days. 23.49% of the stock is owned by insiders.

Oruka Therapeutics Price Performance

Shares of NASDAQ:ORKA opened at $95.97 on Thursday. Oruka Therapeutics, Inc. has a 1 year low of $25.23 and a 1 year high of $115.51. The firm has a market capitalization of $6.35 billion, a price-to-earnings ratio of -47.28 and a beta of -0.37. The business’s 50 day moving average price is $88.89 and its 200-day moving average price is $68.23.

Oruka Therapeutics (NASDAQ:ORKA) last announced its earnings results on Monday, August 10th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.04). On average, sell-side analysts expect that Oruka Therapeutics, Inc. will post -2.42 earnings per share for the current year.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc (NASDAQ: ORKA) is a clinical-stage biopharmaceutical company developing long-acting antibody therapies for immune-mediated diseases. The company is focused on creating treatments that may provide durable disease control while reducing the frequency of administration compared with conventional biologic therapies.

Oruka’s pipeline is centered on engineered monoclonal antibodies that target the interleukin-17 (IL-17) pathway, an important driver of inflammation in conditions such as psoriasis and other autoimmune diseases.